Combination therapy for CLL with TP53 changes
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (epcoritamab, venetoclax, and ibrutinib) in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have changes in the TP53 gene. The goal is to see if this combination can effectively treat the disease in patients who have not had prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 79 years old.
- You have been diagnosed with CLL or SLL and have a TP53 abnormality (like 17p deletion or TP53 mutation).
- You have not received any prior treatment for CLL or SLL.
- Your disease requires treatment based on standard guidelines.
- You have measurable disease, such as a high lymphocyte count, enlarged lymph nodes, or bone marrow involvement.
- You are generally in good health (able to care for yourself, no severe heart or liver problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three drugs for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment yet. The goal is to see if this approach helps control the disease with fewer side effects.
This trial tests a combination of three drugs—nemtabrutinib, venetoclax, and obinutuzumab—for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if this combination is safe and effective in treating the disease.
This trial is testing a combination of three targeted drugs (tafasitamab, acalabrutinib, and venetoclax) for people with CLL or SLL who have not yet received treatment. The goal is to see if this combination is effective and manageable.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose CLL/SLL has come back after prior treatment. The goal is to see if this combination can control the cancer and possibly allow a treatment-free period.
This trial tests two oral targeted drugs—pirtobrutinib and venetoclax—for people with CLL or SLL whose disease has continued to grow despite taking a BTK inhibitor (such as ibrutinib, acalabrutinib, or zanubrutinib). The goal is to see if this combination can control the cancer when a BTK inhibitor alone is no longer working.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.